Team:Evry/Achievements

From 2013.igem.org

(Difference between revisions)
Line 7: Line 7:
<br>
<br>
<p>
<p>
-
Here we detail how we fulfilled each of the <a href="https://2013.igem.org/Judging/Awards" target='_blank'>iGEM medal requirements</a>.
+
Here we detail how we fulfilled each of the <a href="https://2013.igem.org/Judging/Awards" target='_blank'><em>iGEM medal requirements</em></a>.
</p>
</p>
Line 17: Line 17:
<li class="tick">Help any registered iGEM team</li>
<li class="tick">Help any registered iGEM team</li>
-
<li class="tick">As our project involves treating a human genetic disorder using genetically-engineered bacteria, it has numerous implications for human health, safety and security, and ethics. To enable safe delivery of therapeutic bacteria to the human intestine, we designed and constructed a <a href="https://2013.igem.org/Team:Evry/Pill_design"> polymer-based capsule</a>. We also explored safety and ethics consequences of our project as the Human Practices studies:
+
<li class="tick">As our project involves treating a human genetic disorder using genetically-engineered bacteria, it has numerous implications for human health, safety and security, and ethics. To enable safe delivery of therapeutic bacteria to the human intestine, we designed and constructed a <a href="https://2013.igem.org/Team:Evry/Pill_design"><em> polymer-based capsule</em></a>. We also explored safety and ethics consequences of our project as the Human Practices studies:
<ol>
<ol>
-
<li > We discussed the medical feasibility and implications of this treatment in a <a href="https://2013.igem.org/Team:Evry/HumanPractice/Expert_consultation" target='_blank'>series of interviews and discussions</a> with renowned experts on iron overload diseases.</li>
+
<li > We discussed the medical feasibility and implications of this treatment in a <a href="https://2013.igem.org/Team:Evry/HumanPractice/Expert_consultation" target='_blank'><em>series of interviews and discussions</em></a> with renowned experts on iron overload diseases.</li>
-
<li>We carefully analyzed the <a href="https://2013.igem.org/Team:Evry/Safety" target='_blank'>safety issues</a> and potential consequences of our bacteria using consequence-based decision tree.</li>
+
<li>We carefully analyzed the <a href="https://2013.igem.org/Team:Evry/Safety" target='_blank'><em>safety issues</em></a> and potential consequences of our bacteria using consequence-based decision tree.</li>
-
  <li>We organized and hosted a <a href="https://2013.igem.org/Team:Evry/Seminar" target='_blank'>scientific conference</a> on iron overload disorders and perceptions of our our project on 18 September 2013. This conference was attended by both medical experts and iron disorder patients.</li>
+
  <li>We organized and hosted a <a href="https://2013.igem.org/Team:Evry/Seminar" target='_blank'><em>scientific conference</em></a> on iron overload disorders and perceptions of our our project on 18 September 2013. This conference was attended by both medical experts and iron disorder patients.</li>
-
<li> We prepared and disseminated a <a href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions" target='_blank'> patient perception survey</a> about how our treatment could potentially help hemochromatosis patients. We received and analyzed the results from over 250 patients who responded to our survey.</li>
+
<li> We prepared and disseminated a <a href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions" target='_blank'><em> patient perception survey</em></a> about how our treatment could potentially help hemochromatosis patients. We received and analyzed the results from over 250 patients who responded to our survey.</li>
-
<li>We wrote an extensive report on our <a href="https://2013.igem.org/Team:Evry/Philosophy">conclusions about how synthetic biology can treat genetic disorders</a>, which is the fruit of our many discussions over the summer.</li>
+
<li>We wrote an extensive report on our <a href="https://2013.igem.org/Team:Evry/Philosophy" target='_blank'>><em>conclusions about synthetic biology </em></a>, which is the fruit of our many discussions over the summer.</li>
</ol>
</ol>
Line 40: Line 40:
<p>
<p>
<ul>
<ul>
-
<li class="tick">We experimentally validated that the aceB-sfGFP biobrick acts as an iron-reponsive biosensor (<a href="https://2013.igem.org/Team:Evry/Results">see Fig 3 of Biology Results Section</a>).   
+
<li class="tick">We experimentally validated that the aceB-sfGFP biobrick acts as an iron-reponsive biosensor (<a href="https://2013.igem.org/Team:Evry/Results" target='_blank'><em>see Fig 3 of Biology Results Section</em></a>).   
<li class="tick">We document the characterization of our aceB-sfGFP and other BioBricks in "Main Page" section of the Parts Registry.
<li class="tick">We document the characterization of our aceB-sfGFP and other BioBricks in "Main Page" section of the Parts Registry.
-
<li class="tick">We submitted the following BioBricks parts to the iGEM Parts Registry. The 4 sGFP constructs function as <a href="https://2013.igem.org/Team:Evry/Sensor">iron sensors</a> and the lacI constructs are used to build a <a href="https://2013.igem.org/Team:Evry/Inverter">Fur-based genetic inverter</a> that activates gene expression in response to iron. These 8 Biobricks have been <a href="http://parts.igem.org/cgi/dna_transfer/batch_list.cgi?group_id=1475">received and accepted</a> by the Registry of Standard Biological Parts.
+
<li class="tick">We submitted the following BioBricks parts to the iGEM Parts Registry. The 4 sGFP constructs function as <a href="https://2013.igem.org/Team:Evry/Sensor" target='_blank'><em>iron sensors</em></a> and the lacI constructs are used to build a <a href="https://2013.igem.org/Team:Evry/Inverter" target='_blank'><em>Fur-based genetic inverter</em></a> that activates gene expression in response to iron. These 8 Biobricks have been <a href="http://parts.igem.org/cgi/dna_transfer/batch_list.cgi?group_id=1475" target='_blank'><em>received and accepted</em></a> by the Registry of Standard Biological Parts.
<small>
<small>
<ul>
<ul>
-
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163102:Experience" target='_blank'>BBa_K1163102</a>: AceB-sfGFP characterization
+
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163102:Experience" target='_blank'><em>BBa_K1163102</em></a>: AceB-sfGFP characterization
-
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163103:Experience" target='_blank'>BBa_K1163103</a>: AceB-lacI characterization
+
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163103:Experience" target='_blank'><em>BBa_K1163103</em></a>: AceB-lacI characterization
-
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163105:Experience" target='_blank'>BBa_K1163105</a>: FepA-sfGFP characterization
+
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163105:Experience" target='_blank'><em>BBa_K1163105</em></a>: FepA-sfGFP characterization
-
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163106:Experience" target='_blank'>BBa_K1163106</a>: FepA-lacI characterization
+
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163106:Experience" target='_blank'><em>BBa_K1163106</em></a>: FepA-lacI characterization
-
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163108:Experience" target='_blank'>BBa_K1163108</a>: Fes-sfGFP characterization
+
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163108:Experience" target='_blank'><em>BBa_K1163108</em></a>: Fes-sfGFP characterization
-
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163109:Experience" target='_blank'>BBa_K1163109</a>: Fes-lacI characterization
+
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163109:Experience" target='_blank'><em>BBa_K1163109</em></a>: Fes-lacI characterization
-
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163111:Experience" target='_blank'>BBa_K1163111</a>: YncE-sfGFP characterization
+
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163111:Experience" target='_blank'><em>BBa_K1163111</em></a>: YncE-sfGFP characterization
-
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163112:Experience" target='_blank'>BBa_K1163112</a>: YncE-LacI characterization
+
<li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163112:Experience" target='_blank'><em>BBa_K1163112</em></a>: YncE-LacI characterization
</ul>
</ul>
-
</small>    <li class="tick">We describe how our project has implications for <b><a href='https://2013.igem.org/Team:Evry/Safety' target='_blank'>safety</a></b> and <b><a href='https://2013.igem.org/Team:Evry/Philosophy" target='_blank'>ethics</a></b>
+
</small>    <li class="tick">We describe how our project has implications for <b><a href='https://2013.igem.org/Team:Evry/Safety' target='_blank'><em>safety</em></a></b> and <b><a href='https://2013.igem.org/Team:Evry/Philosophy" target='_blank'><em>ethics</em></a></b>
</ul>
</ul>
Line 67: Line 67:
<p>
<p>
<ul>
<ul>
-
<li class="tick">We <a href="https://igem.org/Team_List?year=2013"> registered our team</a> for iGEM 2013 and are attending the European Regional Jamboree.
+
<li class="tick">We <a href="https://igem.org/Team_List?year=2013"><em> registered our team</em></a> for iGEM 2013 and are attending the European Regional Jamboree.
-
<li class="tick">We completed and submitted the <a href='https://igem.org/2013_Judging_Form?id=1163' target='_blank'>Judging form</a>.
+
<li class="tick">We completed and submitted the <a href='https://igem.org/2013_Judging_Form?id=1163' target='_blank'><em>Judging form</em></a>.
-
<li class="tick">We made a comprehensive and accessible <a href="https://2013.igem.org/Team:Evry">iGEM Evry 2013 Wiki</a> to convey our educational and scientific advances.
+
<li class="tick">We made a comprehensive and accessible <a href="https://2013.igem.org/Team:Evry"><em>iGEM Evry 2013 Wiki</em></a> to convey our educational and scientific advances.
<li class="tick">We will present a poster and give an oral presentation at the iGEM European Jamboree in Lyon, France.</b>
<li class="tick">We will present a poster and give an oral presentation at the iGEM European Jamboree in Lyon, France.</b>
-
<li class="tick">We <a href='https://2013.igem.org/Team:Evry/Parts' target='_blank'>document 22 BioBricks</a></b> used in our project and submit 8 news BioBricks to the Parts Registry (see 8 submitted Biobricks in Silver Medal Requirements).
+
<li class="tick">We <a href='https://2013.igem.org/Team:Evry/Parts' target='_blank'><em>document 22 BioBricks</em></a></b> used in our project and submit 8 news BioBricks to the Parts Registry (see 8 submitted Biobricks in Silver Medal Requirements).
</ul>
</ul>

Revision as of 13:35, 4 October 2013

Iron coli project

iGEM Evry 2013 achievements


Here we detail how we fulfilled each of the iGEM medal requirements.

Gold MedalGold Medal (requires any one of the following goals)

  • Improve the function of an existing BioBrick Part or Device: we characterize the LacO-RFP BioBrick and improve it by integrating it with an aceB-LacI iron sensor.
  • Help any registered iGEM team
  • As our project involves treating a human genetic disorder using genetically-engineered bacteria, it has numerous implications for human health, safety and security, and ethics. To enable safe delivery of therapeutic bacteria to the human intestine, we designed and constructed a polymer-based capsule. We also explored safety and ethics consequences of our project as the Human Practices studies:
    1. We discussed the medical feasibility and implications of this treatment in a series of interviews and discussions with renowned experts on iron overload diseases.
    2. We carefully analyzed the safety issues and potential consequences of our bacteria using consequence-based decision tree.
    3. We organized and hosted a scientific conference on iron overload disorders and perceptions of our our project on 18 September 2013. This conference was attended by both medical experts and iron disorder patients.
    4. We prepared and disseminated a patient perception survey about how our treatment could potentially help hemochromatosis patients. We received and analyzed the results from over 250 patients who responded to our survey.
    5. We wrote an extensive report on our >conclusions about synthetic biology , which is the fruit of our many discussions over the summer.

Silver MedalSilver Medal (requires each of the four following goals)


Bronze MedalBronze Medal (requires each of the five following goals)

  • We registered our team for iGEM 2013 and are attending the European Regional Jamboree.
  • We completed and submitted the Judging form.
  • We made a comprehensive and accessible iGEM Evry 2013 Wiki to convey our educational and scientific advances.
  • We will present a poster and give an oral presentation at the iGEM European Jamboree in Lyon, France.
  • We document 22 BioBricks used in our project and submit 8 news BioBricks to the Parts Registry (see 8 submitted Biobricks in Silver Medal Requirements).